Microfragmented Adipose Tissue: A Promising New Approach for Joint Pain and Cartilage Repair
If you or someone you know lives with osteoarthritis (OA), you’re familiar with the frustration: joint pain that won’t go away, treatments that only temporarily ease discomfort, and the fear of cartilage degeneration getting worse over time. In China, 8.1% of adults have symptomatic knee OA—pain paired with visible joint damage—and that number is rising as the population ages. The problem? Articular cartilage has no blood vessels, nerves, or lymph, so it can’t heal itself. Common treatments like anti-inflammatories, hyaluronic acid (HA), or platelet-rich plasma (PRP) offer short-term relief but don’t stop cartilage breakdown.
Enter microfragmented adipose tissue (MAT), a cutting-edge therapy that uses a patient’s own fat to target both pain and underlying cartilage damage. Developed by researchers at the Department of Orthopaedic Surgery at Peking Union Medical College Hospital (Chang Han and Xi-Sheng Weng), MAT is gaining attention for its ability to reduce pain, improve joint function, and avoid the side effects of more invasive treatments.
What Is Microfragmented Adipose Tissue (MAT)?
MAT is made from a small amount of fat (about 60 mL) taken from a patient’s abdomen or other fat-rich area via gentle liposuction. Unlike traditional fat processing—which uses enzymes to break down tissue—MAT is prepared using a closed, saline-filled system that “microfragments” the fat without chemicals. The result is a thick, nutrient-rich substance that retains:
- Mesenchymal stem cells (MSCs): Stem cells that can turn into cartilage, bone, or fat cells.
- Growth factors: Proteins that stimulate tissue repair (e.g., hepatocyte growth factor, placenta growth factor).
- Pericytes: Cells that line tiny blood vessels and secrete anti-inflammatory cytokines.
Crucially, MAT keeps the “stromal vascular niche”—the natural environment that supports stem cell activity—intact. This means the therapy works with the body’s own healing systems, not against them.
How MAT Works: Science Simplified
The magic of MAT lies in two key abilities:
- Tissue Repair: The MSCs and growth factors in MAT help “fill in” damaged cartilage and support new tissue growth. Since cartilage relies on diffusion (not blood flow) for nutrient delivery, MAT’s gel-like structure makes it easy to inject directly into the joint.
- Anti-Inflammatory Effects: MAT’s pericytes and secreted cytokines reduce swelling and pain. In mouse studies, MAT injection cut sepsis-induced inflammation by targeting harmful immune cells. Unlike steroids or opioids, this effect is long-lasting—MAT maintains its anti-inflammatory activity for up to 28 days, compared to just a week for unprocessed fat.
A 2018 study in Stem Cells Translational Medicine found MAT has 2–3 times more pericytes than enzyme-processed fat (called stromal vascular fraction, or SVF). These pericytes stay attached to tiny blood vessels in MAT, preserving their ability to heal and reduce inflammation.
Animal Studies: Proof of Safety and Efficacy in Dogs
To test MAT’s potential for joint repair, researchers turned to dogs—one of the best animal models for human OA. A 2018 study in Stem Cells Translational Medicine treated 130 dogs with spontaneous knee OA using a single MAT injection. The results were striking:
- 88% of dogs showed improved mobility (less limping) after 6 months.
- 97% had reduced pain (measured by the Helsinki Chronic Pain Index).
- Radiographs showed cartilage lesions filling in and less joint fluid buildup.
Most importantly, there were no treatment-related complications. For dogs (and their owners), MAT offered long-term relief with just one injection—unlike PRP, which often requires multiple sessions.
Early Clinical Wins: From Shoulder Pain to Knee OA
Human studies are still in their early stages, but the results are promising:
Shoulder Pain Relief
Twenty patients with chronic shoulder pain (from rotator cuff tears or OA) received MAT injections. After 12 months:
- Pain scores dropped significantly (measured by the Numerical Pain Scale).
- Shoulder function improved steadily (American Shoulder and Elbow Surgeons Score).
- No adverse events were reported—thanks to MAT’s anti-inflammatory cytokines and autologous (patient-derived) source.
Knee OA: Cases and Small Trials
- A 59-year-old man with severe knee pain (after failed meniscus surgery) got MAT injections. Six months later, his pain score dropped from 8/10 to 0, and MRI showed his joint space doubled (from 0.75mm to 1.5mm).
- A 33-year-old man with post-surgical knee pain (microfracture and PRP didn’t work) got MAT. His pain vanished within 6 weeks, and he regained full function for 30 months—no limits on physical activity.
- A 2018 study of 38 knee OA patients (with cartilage damage grade >II) found 92% improved after MAT injections (paired with minor arthroscopic surgery). All patients were satisfied, and none had complications—even 14 who had meniscectomies (a procedure that usually speeds OA progression).
Regulatory Backing and What’s Next
MAT isn’t just experimental—it’s already approved by major health agencies:
- U.S. FDA: Cleared for use in soft tissue repair.
- EU CE Mark: Approved for joint and tendon injuries.
- Australian TGA: Registered for musculoskeletal conditions.
Doctors are now testing MAT in larger trials, comparing it to HA, PRP, and placebo to confirm its superiority. Researchers are also exploring how MAT’s MSCs interact with cartilage cells (chondrocytes) to unlock its full healing potential.
Limitations and Future Directions
MAT isn’t a “cure” for OA—yet. Key gaps remain:
- Small trial sizes: Most studies have fewer than 50 patients.
- Short follow-up: Long-term effects (beyond 2–3 years) are unproven.
- Lack of head-to-head trials: We don’t yet know how MAT stacks up against standard treatments like PRP or HA in large groups.
But the early evidence is clear: MAT offers a safe, one-time treatment that targets both pain and cartilage damage—something no other therapy does. For patients tired of temporary fixes, this could be a game-changer.
Chang Han and Xi-Sheng Weng are researchers at the Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences. Their work on MAT was published in the Chinese Medical Journal in 2019.
doi.org/10.1097/CM9.0000000000000518
Was this helpful?
0 / 0